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  3 
Background: Our aim was to study the relationship between HbA1c and cardiovascular 4 
morbidity and all-cause mortality among older insulin-treated patients with type 2 diabetes 5 
after adjustment for multiple confounders. 6 
Methods: Data for 4589 adults with type 2 diabetes (>65yrs) on insulin treatment were 7 
sourced from 532 UK General Practices via the Health Improvement Network (THIN) 8 
database. Cox proportional hazard models and Kaplan-Meier estimators were fitted to derive 9 
the hazards of all-cause mortality by HbA1c categories (less than 6.5%, 6.5-7.4%, 7.5-8.4%, 10 
8.5-9.4%, 9.5%-10.4%, 10.5-11.4%; and 11.5% and above) after 5-yrs of follow-up following 11 
insulin initiation. 12 
Results:  We observed a U-shaped relationship between all-cause mortality and HbA1c, with 13 
the lowest risk seen in the HbA1c range of 6.5 - 7.4% and marked increased in risk with 14 
HbA1c >11%.  The highest mortality risks of 31% and 40% were significantly associated with 15 
the lowest (less than 6.5%) and highest (11.5% and above) HbA1c categories: aHR: 1.31; 16 
(95%CI: 1.10 – 1.56; p = 0.002) and aHR: 1.40; (95%CI: 1.01 – 1.96; p = 0.039) 17 
respectively.  18 
Conclusions:  Both low and high HbA1c were associated with increased all-cause mortality, 19 
among older patients with insulin-treated type 2 diabetes. This cohort study supports the need 20 
for individualisation of care and suggests better outcomes with HbA1c levels around 6.5 - 21 
7.4%, and markedly excess risk with HbA1c >11% 22 
3 
 
Key messages 1 
What is already known about this subject? 2 
 Older patients account for a larger proportion of patients with type 2 diabetes. 3 
 Recent guideline have emphasised the need to individualised HbA1c target for patients 4 
with type 2 diabetes. 5 
 The optimal HbA1c target for older patients on insulin, which takes into account the 6 
risk benefit of insulin is unknown. 7 
 8 
What does this study add? 9 
 There is a U-Shape association between HbA1c and risk of mortality among older (age 10 
>65 years) insulin-treated patients with Type 2 diabetes.  11 
 12 
How might this impact on clinical practice 13 
In older patients with insulin-treated Type 2 diabetes, very tight and very poor glucose 14 
control is associated with excess mortality. This suggest the need to take into account the risk 15 




More than 25% of all patients with type 2 diabetes (T2D) are aged over 65 years [1], and the 2 
risk-benefit balance for anti-hyperglycaemic therapies can vary considerably in older 3 
compared with younger age groups.  The UK Prospective Diabetes Study (UKPDS) excluded 4 
patients >65 yrs [2] and more recent outcome trials in T2D [3,4,5], have failed to provide a 5 
clear consensus on the optimal HbA1c target for older patients, especially those who are on 6 
insulin therapy. 7 
Outcomes modelling suggests that the cardiovascular and mortality benefits of lowering 8 
HbA1c can take 2 or more decades to manifest [6].  Thus, when treatments have limited or 9 
delayed benefits, the risk-benefit balance changes with increasing age.  This is particularly so 10 
with the use of insulin treatment in older patients in whom the benefits of HbA1c lowering 11 
may be offset by the increased risks of hypoglycaemia, frailty, cardiovascular disease, 12 
cognitive impairment and falls [7]. Indeed large epidemiological studies have observed a 13 
dose-response relationship between increasing insulin exposure and all-cause mortality [8-14 
10].  15 
International guidelines emphasise the importance of individualising HbA1c targets and 16 
recommend a less stringent approach in older patients with longer duration diabetes [11-13]. 17 
Nevertheless, failing to adequately treat hyperglycaemia in older patients may increase the 18 
risk of acute metabolic events [14] morbidity and mortality [15].  We therefore sought to 19 
evaluate the relationship between all-cause mortality and a 2-point composite of 20 
cardiovascular events vs. HbA1c among a large UK cohort of older patients with insulin-21 





Study Design and Data Sources 3 
We conducted a retrospective cohort study using data obtained from UK Primary Care 4 
practices via The Health Improvement Network (THIN). THIN contains anonymised 5 
longitudinal records for more than 10.5 million patients (derived from 532 UK General 6 
Practices) which are representative of the whole UK population in terms of demography, 7 
mortality rates and the prevalence of major health conditions [16,17] and validated for  8 
diabetes-related outcomes. [18,19] Ethical approval for the present study was obtained from 9 
the South East Research Ethics Committee. 10 
Study Population 11 
This comprised older patients with T2D, aged 65 years and above and first ever initiated 12 
insulin therapy in their lifetime, between January 2007 and January 2013, irrespective of use 13 
of other antidiabetic drug combinations. Subsequently, they must have been on insulin 14 
therapy for at least 180 days, from index date to be eligible for inclusion in the study. For 15 
analysis of composite non-fatal MI and stroke, we excluded patients with previous 16 
cardiovascular events at baseline.   17 
Covariates 18 
Baseline covariates were extracted within 90 days of initiation of insulin. These consist of 19 
clinical and biochemical parameters such as body weight, body mass index (BMI) and blood 20 
pressure (systolic and diastolic); baseline HbA1c, serum albumin creatinine ratio, estimated 21 
glomerular filtration rate (eGFR) total cholesterol levels, low-density lipoprotein (LDL), 22 
high-density lipoprotein (HDL) and triglycerides. Additionally,  baseline demographic 23 
parameters (e.g. age, sex, socioeconomic deprivation score, alcohol and smoking status), 24 
medications, e.g. statins, aspirin, antihypertensive drugs and non-insulin antidiabetic drugs; 25 
co-morbidities; as well as the duration of diabetes, duration of insulin treatment and the 26 
overall duration of diabetes treatment were also included. 27 
Procedure 28 
Glycaemic control was measured by post-index mean HbA1c. This was calculated as the 29 
mean of all recorded post-insulin HbA1c values from the index date to earliest of the 30 
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following – mortality, loss to follow-up, discontinuation of insulin (i.e. no records of insulin 1 
prescription for a continuous period greater than 6 months) or end of the study period at 5 2 
years. These mean HbA1c were categorised into the following 7 categories: Less than 6.5%, 3 
6.5-7.4%, 7.5-8.4%, 8.5-9.4%, 9.5%-10.4%, 10.5-11.4%; and 11.5% and above. 4 
The hazard of all-cause mortality and a two-point composite of non-fatal stroke and MI was 5 
explored in each HbA1c categories and compared to the HbA1c range: 6.5 to 7.4%. Both 6 
endpoints must have occurred at least 180 days after the index date 7 
Statistical Analyses 8 
The primary outcome was all-cause mortality while the secondary outcome was a 2-point 9 
composite of non-fatal MI and stroke. The mean, frequency distribution and differences 10 
between the measured baseline covariates between the HbA1c categories were calculated and 11 
summarized.  Using the HbA1c categories, the baseline covariates of the cohort were assessed 12 
independently using linear regression or as trend Pearson’s Chi-square test.  13 
Crude and adjusted Kaplan–Meier estimates of survival functions were obtained. We used the 14 
log-rank test to compare the equality of the survival curves between the categories of HbA1c. 15 
From these survival functions, the absolute reduction in the probability of an event occurring 16 
within a 5-year follow-up was calculated.  17 
We fitted a Cox proportional hazard model to estimate the marginal hazard ratios, to enable 18 
us to quantify the adjusted hazard of mortality in all the HbA1c categories, using the HbA1c 19 
range of 6.5 to 7.4% as the reference. This is because 7.5% is current NICE threshold for 20 
insulin treatment while 6.5% is the target HbA1c for newly diagnosed diabetes. 21 
 In the adjusted model, all the covariates which showed significant association with both the 22 
exposure and outcome in our univariate analyses and changed the effect size by ≥10% were 23 
included alongside a priori confounders (i.e. mean age and diabetes duration) [18,19]. 24 
Proportional hazards assumptions were confirmed through Schoenfeld residuals test. Point 25 
estimates with 95% confidence intervals (CI) at the conventional statistical significance level 26 
of 0.05 were used in the regression models.  27 
We observed that 11%, 13%, 17%, 17% and 16% of the patients did not have baseline HbA1c, 28 
weight, systolic and diastolic BP, and BMI respectively. These missing data were computed 29 
using multiple imputations using the chained equation (MICE) model. 30 
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All analyses were conducted using Stata Software, version 15. Statistical significance was put 1 
at a p-level of 0.05.  The study was reported using the STROBE criteria for reporting 2 




Patient Characteristics 2 
There were 4,589 eligible patients that met the inclusion criteria. Figure 1 outlines the 3 
selection process for these study cohort. At baseline, the overall median age was 73.2 yrs 4 
(SD: 6.1); mean HbA1c: 8.5% (SD: 1.8); 52.5% were females; while the mean BMI was 5 
31.9±6.6 kg/m2 and the average duration of insulin treatment was 3.4±1.2 years.  Supplement 6 
1 summarises the baseline characteristics of our study cohort by HbA1c groups. Significant 7 
differences between the HbA1C   categories were observed in socio-economic status (p = 8 
0.05), gender (p = 0.021), history of alcohol intake (p = 0.048) and use of lipid-lowering 9 
agents (p = 0.001) within the HbA1c categories. 10 
The median follow up period for the cohort was 3.6 years (IQR: 2.3–4.8), representing a total 11 
follow-up period of 26,023 person-years.  12 
 13 
Primary Outcome – All-cause Mortality 14 
A total of 1445 of all-cause mortality was recorded with a crude incidence rate of 56 per 15 
1,000 person-years (95%CI: 52.7–58.5). The lowest proportion of deaths (4.7%) occurred in 16 
≥11.5% HbA1c category, while the highest (33%) occurred in the <6.5% category 17 
(Supplement 2). The 5-year probability of survival differed significantly between the HbA1c 18 
categories. This fell from 98% in all categories at the first year to 74% and 76% at 5 years in 19 
the lowest (<6.5%) and highest (≥11.5%) HbA1c categories respectively (log-rank test p-value 20 
= 0.046) (Figure 2).   21 
In the adjusted Cox regression model, the risk of all-cause mortality was highest in the lowest 22 
and highest HbA1c categories – a 31% significant increase in the hazard of death in the <6.5% 23 
HbA1c category (tight glycaemic control) - HR: 1.31, 95%CI: 1.10–1.56; p=0.002 and a 40% 24 
(HR: 1.40, 95%CI: 1.01–1.96; p=0.039) increase in the HbA1c ≥11.5% category (poor 25 
glycaemic control); thus giving a U-shaped association between post-insulin mean HbA1c and 26 




Secondary Outcome – Composite Cardiovascular Events 1 
A total of 982 composite events of non-fatal MI and stroke events occurred within the follow-2 
up period. The crude incidence rate was 35 per 1,000 person-years (95%CI: 33.2–37.7). The 3 
least proportion (19.1%) was in the highest mean HbA1c category, followed by 20.3% in the 4 
least mean HbA1c category. The 5-year probability of survival for composite cardiovascular 5 
events differed significantly between the HbA1c categories (log-rank test p-value = 0.009) 6 
(Figure 2B).   7 
The risk of the 2-point composite cardiovascular event (Figure 3B), did not show the classical 8 
U-shaped pattern seen in all-cause mortality (Figure 3A). In the adjusted cox model, the risk 9 
increased further away from the comparator HbA1c group of 6.5 to 7.4% in a consistent 10 
pattern (Supplement 2) except in the 8.5 to 9.4% HbA1c category.. Also, there was no 11 
significant association between post-insulin mean HbA1c and the hazard of 2-point composite 12 
cardiovascular events in all the HbA1c groups except in the lowest (<6.5%) HbA1c category in 13 
which the risk was 34% greater (aHR: 1.34; 95%CI: 1.08 – 1.66; p=0.007). Generally, 14 
compared to the 6.5 to 7.4% HbA1c group, the risk of composite cardiovascular events was 4, 15 
2, 12 and 13% higher in the 7.5-8.4%, 9.5-10.4%, 10.5-11.4% and ≥11.5% HbA1c groups 16 
respectively (Supplement  2). 17 
We tested for violations of the proportional hazards assumptions using Schoenfeld residuals 18 
test, in which we examined the null hypothesis that the hazard ratio is constant over time and 19 
we found no evidence (p=0.342) to reject this assumption of proportional hazards for the 20 




We have shown that for older patients (aged >65 years) with Insulin-treated T2Ds, following 2 
adjustment for various confounders, very high and very low levels of HbA1c were associated 3 
with higher risks of adverse outcomes. The highest mortality risks were observed at the 4 
lowest (< 6.5%) and highest (11.5% and above) levels of HbA1c. Interestingly, however, this 5 
U-shaped association between HbA1c and mortality was not observed in the subgroup of 6 
patients with no previous history of a cardiovascular event at baseline. 7 
Intensive control of blood glucose levels in patients with T2D reduces the risk of long-term 8 
vascular complications leading to blindness, kidney failure, lower limb amputation and 9 
adverse cardiovascular events [2,15,20]. Previous observational studies, however, have 10 
provided conflicting evidence regarding the association between achieved HbA1c levels and 11 
mortality among patients with T2D in routine care. Earlier studies s have reported a more 12 
linear relationship [21,22], whereas more recent studies have reported a U-shaped association 13 
between HbA1c and mortality [23-25].  Of note, in a study by Currie et al [23], a U-shaped 14 
association was observed among insulin users, but not apparent among non-insulin treated 15 
patients.  The discrepancies between older and more recent studies are likely to be 16 
attributable to the more aggressive glycaemic targets being adopted in response to recent 17 
national and international guidelines, as well as the greater use of combination therapies 18 
which include insulin.  19 
A post-hoc analysis of the ACCORD trial has revealed a discordant HbA1c-mortality 20 
relationship between the control arm and the intensively treated arm [26], indicating that 21 
aggressive use of glucose-lowering treatments might influence the HbA1c-mortality 22 
relationship. In a more recent sub-analysis of that trial, regardless of intervention arm, the 23 
subgroup of older patients experienced higher annualized rates of severe hypoglycaemia [27].  24 
Thus, the recommendation for individualization of HbA1c targets for older people needs to be 25 
based on a variety of considerations including levels of frailty, presence of multiple 26 
comorbidities and the complexities and safety of polypharmacy.  Yet, despite the well-27 
recognised associations between intensive glucose control and the increased risk of 28 
hypoglycaemia, and the links between hypoglycaemia and enhanced sympathomimetic 29 
(adrenergic) drive [28], cardiac arrhythmias [29] and mortality [30], there is limited data on 30 
defining the appropriate HbA1c-target  range in older patients with insulin treated T2D. 31 
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Our analysis therefore advances current knowledge in several ways: (1) it assessed the 1 
association between HbA1c and mortality specific to older patients with Insulin-treated T2D; 2 
(2) it utilised a large electronic record of individual patient-data among a cohort receiving 3 
routine care in UK General Practice; (3) we derived an association between HbA1c range  4 
with reduction in the risk of mortality, and (4) observed no association between HbA1c range 5 
with composite cardiovascular events  6 
Our findings in older insulin treated patients with T2D are consistent with recent 7 
observational studies in patients with T2D which reported a strong U-shaped HbA1c –8 
mortality association. However, rather than aiming to achieve an HbA1c target to below a 9 
certain value, our data suggests the need to control HbA1c to a certain range (6.5 to 7.4%) in 10 
order to maximally reduce mortality.  .   11 
Unlike mortality, we did not observe a clear U-shaped association between cardiovascular 12 
events and HbA1c in this group of patients, but rather a similar cardiovascular risk across all 13 
HbA1c levels. This implies that this older patient cohort are generically at higher risk of 14 
cardiovascular events, irrespective of HbA1c levels,  and that other non- cardiovascular 15 
factors may influence mortality outcomes at high or low levels of HbA1c. Older patients at 16 
low levels of HbA1c may have poor nutritional status and are generally more frail, whereas 17 
those with higher HbA1c may have a higher risk of dehydration, infection, electrolyte 18 
abnormalities and metabolic complications [7], all of which may contribute to an elevated 19 
mortality risk, independent of cardiovascular events. A discrepancy between mortality and 20 
cardiovascular outcomes was also observed in the ACCORD study where, despite an increase 21 
in mortality with intensive glucose control, the number of patients achieving the composite of 22 
non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes was 23 
lower in the intensive compared with the standard therapy groups. [3].  24 
Our analyses were subject to some limitations inherent to observational studies, such as 25 
coding errors, unlisted comorbidities or missing data.  In addition, our exposure data relates 26 
to prescriptions so we cannot be certain that the patients were completely compliant with 27 
their medication. However, should there be any over-estimation of exposure to the 28 
medications in our analysis, such a misclassification would be non-differential and only bias 29 
results towards unity. Furthermore, other factors apart from HbA1c may also influence the 30 
decision to intensify treatment by starting insulin, such as tolerability, safety, cost and a 31 
patient’s preference. .  Although we could not account for potential residual confounders such 32 
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as indications for intensification of treatment, censuring influenced by patients’ condition or 1 
differences in doses, we were able to account for differences in the observed covariates and 2 
we used robust analytical techniques to control confounding that may bias the results of the 3 
estimated treatment effects.  Nonetheless, the issue of unmeasured confounding does persist, 4 
e.g. the relationship between severity of risk factors and clinical outcomes or differences in 5 
the time-varying relationship for each risk factor with individual outcomes.  6 
Recent local and international guidelines have emphasised the importance of individualised 7 
HbA1c targets to take into account patient factors such as age, body mass index, comorbidities 8 
or duration of diabetes. This is particularly relevant when determining the safety profile of 9 
insulin treatment in older patients. Our data supports a strong U-shaped association between 10 
HbA1c and mortality with minimum safe and high HbA1c values identified to reduce the risks 11 
of mortality in this high risk group of patients in routine care. The observational data 12 
presented here therefore provide important guidance to the management of the rapidly 13 
growing number of older patients with T2D who require insulin therapy to manage their 14 
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Supplement 1: Baseline Characteristics of Study Cohort 
 
Supplement 2: Events and Rates and Hazard Ratio of All-cause Mortality and composite 




Figure 1: Flow diagram of selection of study participants 
 
Figure 2: Kaplan-Meier Survival analysis plot for (A) All-cause Mortality (log-rank test p 
value = 0.046). (B) 2-point composite Cardiovascular (non-fatal MI and stroke) events (log-
rank test p value = 0.009) 
 
Figure 3: Graph of Adjusted Hazard Ratios for All-cause mortality (A) and 2-point 
composite Cardiovascular (non-fatal MI and stroke) events (B) (The vertical bars show 95% 
CI while the horizontal bars show the mean HbA1c range. * Shows truncation of range at the 
upper and/or lower range limit). 
 
Supplement figure 1 HbA1c  categories  calculated as mean of all values, yearly mean, 
accumulative mean,.
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